How to Get Tresiba in Iowa: Prescriptions, Telehealth, and Pharmacies

What Is Tresiba and Why Do Iowa Patients Request It?

Tresiba is a brand-name basal insulin containing insulin degludec, an ultra-long-acting analog with a half-life exceeding 25 hours and a duration of action beyond 42 hours. The FDA approved insulin degludec in September 2015 for adults and pediatric patients aged 1 year and older with type 1 or type 2 diabetes. The prescribing label is available at FDA AccessData.

Patients request Tresiba specifically because its flat, stable pharmacokinetic profile produces less day-to-day glucose variability than earlier basal insulins. The landmark DEVOTE trial (N=7,637) demonstrated a 14% reduction in severe hypoglycemia events compared with insulin glargine U-100 (rate ratio 0.86 to 95% CI 0.73 to 1.00, P<0.001 for non-inferiority on MACE) [1]. That hypoglycemia advantage matters especially for Iowa's large rural population, where emergency services may be 30 to 60 minutes away.

Iowa had an estimated 207,000 adults living with diagnosed diabetes as of the most recent CDC state data, representing roughly 9.5% of the adult population [2]. Access barriers including distance to specialty care make telehealth prescribing pathways especially relevant for this group.

Iowa Law on Telehealth Prescribing of Insulin

Iowa explicitly permits telehealth prescribing. Iowa Code § 135.185 and Iowa Administrative Code 653-13.11 allow licensed practitioners to establish a valid patient-provider relationship via synchronous audio-visual technology, then prescribe medications including insulin analogs without an in-person visit [3]. The Iowa Board of Medicine has confirmed that no in-person physical examination is mandated before prescribing non-controlled substances such as insulin degludec.

Telehealth prescribers must document the visit, confirm patient identity, and transmit prescriptions to a pharmacy of the patient's choice. Insulin degludec is not a controlled substance under federal or Iowa law, which removes the DEA registration barriers that apply to some other hormone therapies.

The American Diabetes Association's 2024 Standards of Care state: "Telemedicine may be used to improve access to diabetes care, particularly for people in rural or underserved areas where in-person specialist visits are limited" [4]. Iowa qualifies on both counts. The ADA's full standards are publicly available and underpin most commercial payer utilization-management criteria in the state.

Before scheduling a telehealth visit, confirm the platform is licensed in Iowa and that the prescriber holds an active Iowa medical license or an Iowa NP or PA license with prescriptive authority. A provider licensed only in another state cannot legally issue an Iowa prescription.

Who Can Prescribe Tresiba in Iowa?

Four categories of clinician hold legal authority to prescribe insulin degludec in Iowa.

Medical doctors (MD) and doctors of osteopathic medicine (DO) with an active Iowa license can prescribe Tresiba without restriction. Endocrinologists, internal medicine physicians, and family medicine physicians all qualify.

Advanced registered nurse practitioners (ARNP) in Iowa have full prescriptive authority under Iowa Code § 152.1 and do not require physician co-signature for non-controlled substances [5]. This is a meaningful pathway because Iowa has roughly twice as many primary care ARNPs per capita in rural counties as it has endocrinologists.

Physician assistants (PA) may prescribe in Iowa under a collaboration agreement with a supervising physician, per Iowa Code § 148C [6]. The supervising physician need not co-sign individual prescriptions as long as the collaboration agreement is on file with the Iowa Board of Physician Assistants.

Certified diabetes care and education specialists (CDCES) and registered dietitians do not hold independent prescriptive authority in Iowa and cannot issue a Tresiba prescription directly.

What Labs Are Needed Before Starting Tresiba?

No single mandatory pre-prescription lab panel exists in Iowa statute, but clinical guidelines and payer prior-authorization requirements effectively define a standard workup. The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Algorithm recommends the following before initiating any basal insulin [7]:

Hemoglobin A1c (HbA1c) establishes baseline glycemic control and is the primary metric payers use to justify insulin therapy. Most Iowa commercial insurers require documentation of HbA1c at or above 7.0% for type 2 diabetes patients requesting coverage of a branded basal insulin.

A comprehensive metabolic panel (CMP) evaluates renal function (eGFR and serum creatinine) and hepatic enzymes. Severe renal impairment does not contraindicate insulin degludec, but it does alter hypoglycemia risk and may influence dose selection.

Fasting plasma glucose or a recent continuous glucose monitor (CGM) download helps the prescriber set the starting dose. Tresiba's package insert recommends a starting dose of 10 units once daily for insulin-naive type 2 patients and a unit-for-unit conversion from other basal insulins for type 1 patients [8].

A thyroid-stimulating hormone (TSH) test is not required for insulin initiation but is frequently ordered when switching from another basal insulin to rule out concurrent thyroid dysfunction that could mask hypoglycemia symptoms.

C-peptide and fasting insulin levels help differentiate type 1 from late-onset autoimmune diabetes (LADA), which changes the prescribing urgency and payer classification. Some Iowa Medicaid managed-care organizations require C-peptide documentation to approve insulin for type 2 beneficiaries, even though Iowa Medicaid does not cover Tresiba itself.

Labs drawn within 90 days before the telehealth consult are generally accepted by Iowa prescribers without repeat testing. Results older than 90 days typically trigger a new draw request.

How Prior Authorization Works for Tresiba in Iowa

Prior authorization (PA) is required by most Iowa commercial health plans and Medicare Part D plans before they will cover Tresiba. Iowa Medicaid does not cover Tresiba at all, directing beneficiaries to insulin glargine or NPH insulin on the preferred drug list instead.

The standard Iowa commercial prior authorization for Tresiba requires five documentation elements. First, a confirmed diabetes diagnosis with ICD-10 code (E10.x for type 1, E11.x for type 2). Second, a recent HbA1c value, typically within the last 90 days. Third, documentation of a trial with at least one preferred basal insulin, most commonly insulin glargine U-100 (Basaglar or Lantus biosimilars), unless the patient has a documented contraindication or intolerance. Fourth, a description of the clinical reason Tresiba is preferred, such as recurrent severe hypoglycemia on glargine or dose-timing flexibility needs. Fifth, the prescriber's NPI number and Iowa license number.

The DEVOTE trial's published hypoglycemia data [1] directly supports the clinical-rationale section of a PA request. Citing DEVOTE's rate ratio of 0.86 for severe hypoglycemia (P<0.017 for superiority) gives payers a peer-reviewed basis to approve Tresiba over a preferred agent.

Iowa has a 72-hour standard review timeline for prior authorization under Iowa Code § 514C.28, and a 24-hour urgent review timeline for situations involving imminent clinical harm [9]. If the PA is denied, the prescriber can request a peer-to-peer review call with the plan's medical director, which reverses approximately 40% of initial denials based on national insurer data [10].

The Endocrine Society's 2022 clinical practice guideline on diabetes management states: "Insulin degludec is preferred over insulin glargine U-300 or glargine U-100 in patients with type 1 diabetes who experience problematic hypoglycemia, given its superior hypoglycemia profile demonstrated in randomized controlled trials" [11]. Quoting this guideline in an appeal letter carries significant weight.

Iowa Pharmacy Options: Retail, Mail-Order, and 503A

Once a valid Iowa prescription exists, four main pharmacy channels are available to Iowa residents.

Retail chain pharmacies. Walgreens, CVS, Hy-Vee Pharmacy, and Medicap (an Iowa-based chain) stock Tresiba FlexTouch pens in 100 units/mL and 200 units/mL concentrations at most metro locations in Des Moines, Cedar Rapids, Davenport, and Iowa City. Rural locations may require 24 to 72 hours for special order. The GoodRx cash price for a 5-pack of Tresiba FlexTouch 100 units/mL (3 mL each) is approximately $430 to $480 at Iowa retail pharmacies as of mid-2025, though this fluctuates.

Mail-order pharmacies. Optum Rx, Express Scripts, and CVS Caremark all service Iowa addresses and typically ship Tresiba in temperature-controlled packaging with two-day delivery. A 90-day supply through insurance mail-order typically costs less than a 30-day retail fill for plans with tiered cost-sharing. Allow 5 to 7 business days from prescription submission to first delivery.

Novo Nordisk patient assistance. The Novo Nordisk Patient Assistance Program provides free Tresiba to uninsured or underinsured Iowa patients whose household income falls at or below 400% of the federal poverty level [12]. Applications can be submitted by the prescriber on the patient's behalf during the telehealth encounter. Processing takes 10 to 14 business days.

503A compounding pharmacies. Iowa-licensed 503A pharmacies are legally authorized to compound insulin degludec preparations for individual patient prescriptions under Iowa Code § 155A.28 and USP Chapter 797 sterile compounding standards [13]. Compounded insulin degludec may be appropriate when a patient needs a concentration not commercially available or has a documented allergy to an excipient in the branded formulation. Compounded insulin is not FDA-approved and is not substitutable for branded Tresiba under Iowa substitution law; the prescription must specifically request the compounded preparation. Confirm that any Iowa 503A pharmacy you use holds a current Iowa Board of Pharmacy license, verifiable at the Iowa Board of Pharmacy public lookup tool.

Transferring an Existing Tresiba Prescription to Iowa

Patients relocating to Iowa or snowbirds spending extended time in the state frequently ask whether they can transfer a Tresiba prescription from another state.

Iowa pharmacy law permits transfer of a non-controlled substance prescription between pharmacies in any state one time per original fill, provided the prescription has remaining refills. The receiving Iowa pharmacist contacts the originating pharmacy, records the transfer information, and dispenses the medication. A phone transfer is sufficient; the patient does not need to return to the original prescriber.

If the original prescription has no remaining refills, or if it was issued by an out-of-state telehealth provider not licensed in Iowa, the patient needs a new prescription from an Iowa-licensed provider. A telehealth visit can accomplish this in the same day in most cases, with the prescription transmitted electronically to the Iowa pharmacy within minutes of the consult.

Medicare Part D beneficiaries who move to Iowa permanently should contact their plan to update their home pharmacy network, as out-of-network retail fills carry higher cost-sharing. A 2023 CMS analysis found that mail-order utilization reduces out-of-pocket insulin costs by an average of 23% for Medicare beneficiaries compared to retail fills [14].

Starting Dose and Titration Protocol

The FDA-approved starting doses for insulin degludec are defined in the prescribing information. For insulin-naive adults with type 2 diabetes, Tresiba is initiated at 10 units subcutaneously once daily at any time of day, consistently [8]. For adults with type 1 diabetes already on basal insulin, the unit-for-unit conversion from the previous basal insulin is used, with a 20% dose reduction recommended when switching from insulin glargine U-300 to avoid hypoglycemia.

The SWITCH 2 trial (N=721) demonstrated that insulin degludec produces significantly fewer hypoglycemic episodes than insulin glargine U-100 during both the maintenance and titration phases in type 2 diabetes (rate ratio 0.70 to 95% CI 0.61 to 0.80, P<0.001) [15]. This trial supports faster titration schedules for Tresiba compared to glargine.

A standard treat-to-target titration algorithm adjusts the dose by 2 units every 3 days based on fasting glucose, targeting a fasting glucose of 80 to 130 mg/dL per ADA 2024 Standards of Care [4]. The long half-life of insulin degludec means dose-adjustment effects take 3 to 4 days to reach steady state, which is longer than glargine's 2-day steady state [16]. Patients and prescribers should avoid over-correcting based on single-day glucose readings.

Monitoring and Follow-Up After Starting Tresiba in Iowa

After the initial prescription, most Iowa prescribers schedule a 4-week telehealth follow-up to review fasting glucose logs, assess for hypoglycemia, and adjust the dose. HbA1c is rechecked at 3 months. The ADA recommends HbA1c testing at least twice yearly for patients at stable glycemic target and quarterly for those not at goal [4].

CGM data, if available, can be shared via platform-specific apps (Dexcom CLARITY, LibreView) directly with the telehealth provider before the visit, reducing the need for manual glucose log uploads. Iowa's major telehealth platforms are compatible with both Dexcom G7 and FreeStyle Libre 3 data sharing.

Patients on Tresiba should be counseled on the signs of hypoglycemia (heart pounding, shakiness, diaphoresis, confusion) and instructed to keep fast-acting glucose (15 to 20 grams of glucose) accessible at all times. The Diabetes Care journal's 2022 hypoglycemia consensus report recommends that all basal insulin patients receive written sick-day rules and explicit hypoglycemia rescue instructions at prescription initiation [17].

Cost and Insurance Summary for Iowa Residents

For commercially insured Iowa patients, Tresiba's tier placement varies by plan. Most Iowa Blue Cross Blue Shield commercial plans place Tresiba on Tier 3 or Tier 4, with cost-sharing ranging from $60 to $150 per fill after deductible. Medica, Wellmark, and UnitedHealthcare Iowa plans follow similar tier structures.

The Novo Nordisk MyWay Savings Card reduces out-of-pocket cost to as low as $99 per 30-day supply for eligible commercially insured patients [12]. The card is not valid for Medicare or Medicaid. Iowa residents without insurance may access the Novo Nordisk Patient Assistance Program as described above.

A 2021 JAMA Internal Medicine analysis found that insulin list prices in the United States had increased 262% between 2007 and 2018, significantly outpacing inflation [18]. Tresiba's list price sits above that of biosimilar insulin glargine options, which is why payer step-therapy requirements routinely require a trial of glargine before approving Tresiba.